Ixekizumab improved psoriatic arthritis in patients who had not taken biologics
Two different doses of the humanized monoclonal antibody ixekizumab improved signs and symptoms of active psoriatic arthritis in a phase III manufacturer-sponsored trial of patients who had not taken a biologic drug before.
The agent selectively binds and neutralizes interleukin (IL)-17A, which...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Arthritis | Dermatology | Psoriatic Arthritis | Rheumatology | Skin